d-Allulose supplementation normalized the body weight and fat-pad mass in diet-induced obese mice via the regulation of lipid metabolism under isocaloric fed condition

Mol Nutr Food Res. 2016 Jul;60(7):1695-706. doi: 10.1002/mnfr.201500771. Epub 2016 Apr 24.


Scope: A number of findings suggest that zero-calorie d-allulose, also known as d-psicose, has beneficial effects on obesity-related metabolic disturbances. However, it is unclear whether d-allulose can normalize the metabolic status of diet-induced obesity without having an impact on the energy density. We investigated whether 5% d-allulose supplementation in a high fat diet(HFD) could normalize body fat in a diet-induced obesity animal model under isocaloric pair-fed conditions.

Methods and results: Mice were fed an HFD with or without various sugar substitutes (d-glucose, d-fructose, erytritol, or d-allulose, n = 10 per group) for 16 wk. Body weight and fat-pad mass in the d-allulose group were dramatically lowered to that of the normal group with a simultaneous decrease in plasma leptin and resistin concentrations. d-allulose lowered plasma and hepatic lipids while elevating fecal lipids with a decrease in mRNA expression of CD36, ApoB48, FATP4, in the small intestine in mice. In the liver, activities of both fatty acid synthase and β-oxidation were downregulated by d-allulose to that of the normal group; however, in WAT, fatty acid synthase was decreased while β-oxidation activity was enhanced.

Conclusion: Taken together, our findings suggest that 5% dietary d-allulose led to the normalization of the metabolic status of diet-induced obesity by altering lipid-regulating enzyme activities and their gene-expression level along with fecal lipids.

Keywords: Fecal lipid excretion; Lipogenesis; d-allulose; β-oxidation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiposity / drug effects
  • Animals
  • Apolipoprotein B-48 / genetics
  • Apolipoprotein B-48 / metabolism
  • Blood Glucose / metabolism
  • Body Weight / drug effects*
  • CD36 Antigens / genetics
  • CD36 Antigens / metabolism
  • Diet, High-Fat
  • Dietary Supplements
  • Fatty Acid Transport Proteins / genetics
  • Fatty Acid Transport Proteins / metabolism
  • Fructose / administration & dosage*
  • Gene Expression Regulation
  • Glucose / administration & dosage
  • Leptin / blood
  • Lipid Metabolism / drug effects*
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Obesity / drug therapy*
  • Obesity / etiology
  • Resistin / blood
  • Sweetening Agents / administration & dosage


  • Apolipoprotein B-48
  • Blood Glucose
  • CD36 Antigens
  • Fatty Acid Transport Proteins
  • Leptin
  • Resistin
  • Slc27a4 protein, mouse
  • Sweetening Agents
  • psicose
  • Fructose
  • Glucose